

# Wolfgang C Winkelmayer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4919936/publications.pdf>

Version: 2024-02-01

434  
papers

19,290  
citations

9756

73  
h-index

20307

116  
g-index

446  
all docs

446  
docs citations

446  
times ranked

17952  
citing authors

#	ARTICLE	IF	CITATIONS
1	Child and caregiver perspectives on access to psychosocial and educational support in pediatric chronic kidney disease: a focus group study. <i>Pediatric Nephrology</i> , 2023, 38, 249-260.	0.9	2
2	Diseases of the Aorta and Kidney Disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Cardiovascular Research</i> , 2022, 118, 2582-2595.	1.8	6
3	Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis. <i>Kidney International Reports</i> , 2022, 7, 189-199.	0.4	7
4	Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis. <i>JAMA Cardiology</i> , 2022, 7, 75.	3.0	11
5	Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 928-937.	2.2	2
6	Updated US Prevalence Estimates for Chronic Kidney Disease Stage and Complications Using the New Race-Free Equation to Estimate Glomerular Filtration Rate. <i>JAMA Network Open</i> , 2022, 5, e220460.	2.8	12
7	Cost Barriers to More Widespread Use of Peritoneal Dialysis in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, , ASN.2021060854.	3.0	5
8	Kidney Function, Kidney Replacement Therapy, and Mortality in Men and Women. <i>Kidney International Reports</i> , 2022, 7, 444-454.	0.4	11
9	Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 670-679.	0.9	5
10	US Renal Data System 2021 Annual Data Report: Epidemiology of Kidney Disease in the United States. <i>American Journal of Kidney Diseases</i> , 2022, 79, A8-A12.	2.1	121
11	MO536: Cardiovascular Events in Patients With Anemia Associated With Non-Dialysis-Dependent Chronic Kidney Disease: Regional Analysis of Patients not Previously Treated With Erythropoiesis-Stimulating Agents in The PRO2TECT Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
12	MO532: Cardiovascular Events in Patients With Non-Dialysis-Dependent Chronic Kidney Disease and Anemia: Regional Analysis of Patients Previously Treated With Erythropoiesis-Stimulating Agents in the PRO2TECT Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
13	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2039-2048.	0.4	20
14	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Peritoneal Dialysis International</i> , 2021, 41, 5-14.	1.1	4
15	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. <i>American Journal of Transplantation</i> , 2021, 21, 901-902.	2.6	4
16	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263.	2.1	21
17	A Global Accounting of Kidney Replacement Therapy. <i>American Journal of Kidney Diseases</i> , 2021, 77, 309-311.	2.1	1
18	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021, 99, 34-47.	2.6	195

#	ARTICLE	IF	CITATIONS
19	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021, 235, 1-11.	1.2	9
20	Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 129-136.	0.4	46
21	Ultrafiltration rate and incident atrial fibrillation among older individuals initiating hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2084-2093.	0.4	6
22	Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in Nephrology Practice Across Countries. <i>Kidney International Reports</i> , 2021, 6, 437-448.	0.4	19
23	The impact of COVID-19 on kidney transplantation and the kidney transplant recipient – One year into the pandemic. <i>Transplant International</i> , 2021, 34, 612-621.	0.8	40
24	Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1-5. <i>Hypertension</i> , 2021, 77, 948-959.	1.3	14
25	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 384, 1601-1612.	13.9	106
26	Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension. <i>American Journal of Kidney Diseases</i> , 2021, 78, 700-708.e1.	2.1	4
27	Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. <i>New England Journal of Medicine</i> , 2021, 384, 1589-1600.	13.9	137
28	Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1319-1321.	3.0	10
29	Intradialytic Hypotension and Newly Recognized Peripheral Artery Disease in Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2021, 77, 730-738.	2.1	3
30	MO541 HEMATOLOGIC EFFICACY OF VADADUSTAT FOR ANEMIA IN PATIENTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
31	MO539 HEMATOLOGIC EFFICACY OF VADADUSTAT FOR ANEMIA IN PATIENTS WITH KIDNEY FAILURE ON DIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
32	MO114 NEPHROLITHIASIS AS CAUSE OF KIDNEY FAILURE AND MAJOR CARDIOVASCULAR OUTCOMES IN INCIDENT DIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
33	Black Race Coefficient in GFR Estimation and Prevalence of CKD-Related Complications. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1562-1564.	2.2	1
34	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2021, 99, 1280-1295.	2.6	103
35	Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021, 100, 35-48.	2.6	26
36	Patient-Reported Experiences with Dialysis Care and Provider Visit Frequency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1052-1060.	2.2	0

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Safety of Roxadustat in CKD Anemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1155-1157.	2.2	2
38	The Association of Pre-Kidney Transplant Dialysis Modality with de novo Posttransplant Heart Failure. <i>CardioRenal Medicine</i> , 2021, 11, 209-217.	0.7	3
39	Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2021, 100, 516-526.	2.6	156
40	Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2984-2996.	1.9	10
41	Long-Term Exposures to Air Pollution and the Risk of Atrial Fibrillation in the Women's Health Initiative Cohort. <i>Environmental Health Perspectives</i> , 2021, 129, 97007.	2.8	13
42	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. <i>Kidney International</i> , 2021, 100, 1199-1207.	2.6	23
43	Patient Health Outcomes following Dialysis Facility Closures in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2613-2621.	3.0	3
44	The landscape of renal replacement therapy in Veterans Affairs Medical Center intensive care units. <i>Renal Failure</i> , 2021, 43, 1146-1154.	0.8	5
45	Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1893-1899.	0.4	26
46	Sex Differences in Kidney Transplantation: Austria and the United States, 1978-2018. <i>Frontiers in Medicine</i> , 2021, 8, 800933.	1.2	10
47	Association between intensity of statin therapy and mortality in persons with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 312-319.	0.4	7
48	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	2.6	260
49	Selective Serotonin Reuptake Inhibitor Use and Hip Fracture Risk Among Patients on Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2020, 75, 351-360.	2.1	19
50	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney Medicine</i> , 2020, 2, 373-376.	1.0	3
51	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes Consensus Conference. <i>Transplantation</i> , 2020, 104, 1986-1994.	0.5	4
52	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108248.	1.1	12
53	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. <i>Renal Failure</i> , 2020, 42, 560-566.	0.8	5
54	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney Diseases (Basel)</i> , 2020, 10, 10.	0.2	10

#	ARTICLE	IF	CITATIONS
55	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. <i>Kidney International</i> , 2020, 98, 1407-1418.	2.6	8
56	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Nephrology</i> , 2020, 25, 589-598.	0.7	3
57	Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks – A Narrative Review. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2204-2224.	1.4	46
58	Direct oral anticoagulants in chronic kidney disease: an update. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 489-496.	1.0	9
59	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. <i>Journal of Nephrology</i> , 2020, 33, 639-648.	0.9	5
60	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Seminars in Nephrology</i> , 2020, 40, 329-337.	0.6	1
61	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	2.6	26
62	Editorial: Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes consensus conference. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 537-546.	1.0	1
63	Nephrology and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1137.	3.8	15
64	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Journal of Renal Care</i> , 2020, 46, 136-136.	0.6	3
65	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes consensus conference*. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 485-493.	1.4	11
66	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. <i>Pediatric Nephrology</i> , 2020, 35, 2191-2200.	0.9	4
67	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes consensus conference*. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1077-1084.	0.4	8
68	Nomenclature for kidney function and disease – executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. <i>European Heart Journal</i> , 2020, 41, 4592-4598.	1.0	44
69	Re-estimation improved the performance of two Framingham cardiovascular risk equations and the Pooled Cohort equations: A nationwide registry analysis. <i>Scientific Reports</i> , 2020, 10, 8140.	1.6	10
70	Hip Fracture Risk among Hemodialysis-Dependent Patients Prescribed Opioids and Gabapentinoids. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1325-1334.	3.0	11
71	Nomenclature for kidney function and disease: executive summary from a KDIGO consensus conference. <i>Nature Reviews Nephrology</i> , 2020, 16, 427-428.	4.1	2
72	Safety-Net Care for Maintenance Dialysis in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 424-433.	3.0	5

#	ARTICLE	IF	CITATIONS
73	Bundled Payment Reform and Dialysis Facility Closures in ESKD. Journal of the American Society of Nephrology: JASN, 2020, 31, 579-590.	3.0	10
74	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. American Journal of Kidney Diseases, 2020, 76, 109-120.	2.1	10
75	Glycemic Control and Infections Among US Hemodialysis Patients With Diabetes Mellitus. Kidney International Reports, 2020, 5, 1014-1025.	0.4	3
76	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International, 2020, 97, 1117-1129.	2.6	407
77	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 861-876.	2.6	126
78	Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 937-948.	2.2	47
79	Pre-ESKD Nephrology Care and Employment at the Start of Dialysis. Kidney International Reports, 2020, 5, 821-830.	0.4	4
80	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. American Journal of Nephrology, 2020, 51, 579-588.	1.4	1
81	Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End-Stage Kidney Disease. Journal of the American Heart Association, 2020, 9, e015969.	1.6	9
82	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International Reports, 2020, 5, 965-972.	0.4	7
83	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 1761-1769.	0.4	5
84	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 Diseases, 2020, 75, 404-412.	2.1	92
85	The dialysis careâ€policy issue: Guest Editorsâ€™™ introductory remarks. Seminars in Dialysis, 2020, 33, 4-4.	0.7	0
86	Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study. Scientific Reports, 2020, 10, 5964.	1.6	18
87	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Transplant International, 2020, 33, 999-1009.	0.8	5
88	Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2020, 98, 294-309.	2.6	254
89	Hospitalization and Critical Illness in Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 302-312.	0.7	2
90	Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk. Kidney Medicine, 2020, 2, 341-353.	1.0	24

#	ARTICLE	IF	CITATIONS
91	Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 679-689.	2.1	56
92	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>American Journal of Kidney Diseases</i> , 2020, 76, 157-160.	2.1	8
93	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. , 2020, 30, e41-e50.		2
94	Readmissions after Acute Kidney Injury during Left Ventricular Assist Device Implantation Hospitalization. <i>American Journal of Nephrology</i> , 2020, 51, 172-181.	1.4	7
95	Sex differences in chronic kidney disease awareness among US adults, 1999 to 2018. <i>PLoS ONE</i> , 2020, 15, e0243431.	1.1	32
96	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney Research and Clinical Practice</i> , 2020, 39, 151-161.	0.9	8
97	Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. <i>Nephrology (Saint-Petersburg)</i> , 2020, 24, 22-41.	0.1	10
98	Cloth Masks May Prevent Transmission of COVID-19: An Evidence-Based, Risk-Based Approach. <i>Annals of Internal Medicine</i> , 2020, 173, 489-491.	2.0	68
99	Sex differences in chronic kidney disease awareness among US adults, 1999 to 2018. , 2020, 15, e0243431.		0
100	Sex differences in chronic kidney disease awareness among US adults, 1999 to 2018. , 2020, 15, e0243431.		0
101	Sex differences in chronic kidney disease awareness among US adults, 1999 to 2018. , 2020, 15, e0243431.		0
102	Sex differences in chronic kidney disease awareness among US adults, 1999 to 2018. , 2020, 15, e0243431.		0
103	Market Consolidation and Mortality in Patients Initiating Hemodialysis. <i>Value in Health</i> , 2019, 22, 69-76.	0.1	7
104	Cause of kidney disease and cardiovascular events in a national cohort of US patients with end-stage renal disease on dialysis: a retrospective analysis. <i>European Heart Journal</i> , 2019, 40, 887-898.	1.0	27
105	Acute Kidney Injury With Ventricular Assist Device Placement: National Estimates of Trends and Outcomes. <i>American Journal of Kidney Diseases</i> , 2019, 74, 650-658.	2.1	10
106	A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes. <i>PLoS ONE</i> , 2019, 14, e0218709.	1.1	2
107	Association of Hospitalization and Mortality Among Patients Initiating Dialysis With Hemodialysis Facility Ownership and Acquisitions. <i>JAMA Network Open</i> , 2019, 2, e193987.	2.8	13
108	Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107423.	1.2	2

#	ARTICLE	IF	CITATIONS
109	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
110	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	1.2	403
111	Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 346-353.	3.0	29
112	Blood Pressure and Incident Atrial Fibrillation in Older Patients Initiating Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1029-1038.	2.2	7
113	Predialysis Nephrology Care and Incident Atrial Fibrillation in Older Patients With ESKD Initiating Dialysis. <i>Kidney International Reports</i> , 2019, 4, 679-687.	0.4	2
114	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1027-1036.	2.6	60
115	The TiME Trial: A Fully Embedded, Cluster-Randomized, Pragmatic Trial of Hemodialysis Session Duration. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 890-903.	3.0	38
116	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
117	Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 82-94.	2.1	42
118	Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. <i>Journal of Medical Economics</i> , 2019, 22, 593-604.	1.0	47
119	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 37-47.	2.6	235
120	Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. <i>Pharmacoeconomics - Open</i> , 2019, 3, 463-478.	0.9	18
121	Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients. <i>Kidney International Reports</i> , 2019, 4, 301-309.	0.4	38
122	Association Between Type of Vascular Access Used in Hemodialysis Patients and Subsequent Kidney Transplant Outcomes. <i>Kidney Medicine</i> , 2019, 1, 383-390.	1.0	3
123	Trends in the Medical Complexity and Outcomes of Medicare-insured Patients Undergoing Kidney Transplant in the Years 1998-2014. <i>Transplantation</i> , 2019, 103, 2413-2422.	0.5	5
124	Dialysis Modality and Incident Atrial Fibrillation in Older Patients With ESRD. <i>American Journal of Kidney Diseases</i> , 2019, 73, 324-331.	2.1	18
125	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	2.6	198
126	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	2.6	135



#	ARTICLE	IF	CITATIONS
127	External validation of two Framingham cardiovascular risk equations and the Pooled Cohort equations: A nationwide registry analysis. <i>International Journal of Cardiology</i> , 2019, 283, 165-170.	0.8	14
128	CHRONIC KIDNEY DISEASE AND ARRHYTHMIAS: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. <i>Nephrology (Saint-Petersburg)</i> , 2019, 23, 18-40.	0.1	5
129	Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1590-1597.	0.4	8
130	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2018, 72, 62-74.	2.1	39
131	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	1.0	186
132	Report of the Standardized Outcomes in Nephrology Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. <i>American Journal of Kidney Diseases</i> , 2018, 71, 690-700.	2.1	62
133	Market Competition and Health Outcomes in Hemodialysis. <i>Health Services Research</i> , 2018, 53, 3680-3703.	1.0	16
134	High-density lipoprotein cholesterol and causes of death in chronic kidney disease. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1061-1071.e7.	0.6	15
135	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2018, 93, 1281-1292.	2.6	69
136	Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2018, 93, 545-559.	2.6	147
137	Employment among Patients Starting Dialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 265-273.	2.2	43
138	Health Insurance and the Use of Peritoneal Dialysis in the United States. <i>American Journal of Kidney Diseases</i> , 2018, 71, 479-487.	2.1	20
139	De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. <i>American Journal of Kidney Diseases</i> , 2018, 72, 223-233.	2.1	6
140	Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. <i>Kidney International</i> , 2018, 93, 941-951.	2.6	139
141	Establishing a Core Outcome Measure for Fatigue in Patients on Hemodialysis: A Standardized Outcomes in Nephrology Hemodialysis (SONG-HD) Consensus Workshop Report. <i>American Journal of Kidney Diseases</i> , 2018, 72, 104-112.	2.1	69
142	Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1207-1214.	0.4	39
143	Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014). <i>American Journal of Nephrology</i> , 2018, 48, 472-481.	1.4	131
144	Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation. <i>Seminars in Nephrology</i> , 2018, 38, 618-628.	0.6	25

#	ARTICLE	IF	CITATIONS
145	Clinicians™ and researchers™ perspectives on establishing and implementing core outcomes in haemodialysis: semistructured interview study. <i>BMJ Open</i> , 2018, 8, e021198.	0.8	9
146	Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1842-1850.	2.2	19
147	Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1534-1541.	2.2	16
148	The Relationship between Intradialytic Hypotension and Hospitalized Mesenteric Ischemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1517-1525.	2.2	37
149	Did Medicaid Expansion Reduce Mortality Among Patients Initiating Dialysis for Irreversible Kidney Failure?. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2206.	3.8	3
150	Health Insurance in the First 3 Months of Hemodialysis and Early Vascular Access. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1866-1875.	2.2	13
151	Evaluating the Evidence behind Policy Mandates in US Dialysis Care. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2777-2779.	3.0	7
152	Patient-Reported Experiences of Dialysis Care Within a National Pay-for-Performance System. <i>JAMA Internal Medicine</i> , 2018, 178, 1358.	2.6	24
153	Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1423-1425.	2.2	1
154	Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 547-559.	2.1	46
155	SP338ECONOMIC AND HUMANISTIC BURDEN OF DIALYSIS-DEPENDENT PATIENTS WITH CHRONIC KIDNEY DISEASE-RELATED ANEMIA: A SYSTEMATIC REVIEW. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i458-i459.	0.4	0
156	Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation. <i>American Journal of Nephrology</i> , 2018, 48, 36-45.	1.4	17
157	Trends in Left Ventricular Assist Device Implantation and Associated Mortality Among Patients With and Without ESRD. <i>American Journal of Kidney Diseases</i> , 2018, 72, 620-622.	2.1	7
158	Heterogeneity in Outcomes Among $\beta$ -Blockers Elucidated by Intradialytic Data. <i>American Journal of Kidney Diseases</i> , 2018, 72, 318-321.	2.1	0
159	Cardiovascular Outcomes Reported in Hemodialysis Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2802-2810.	1.2	16
160	The Role of Big Data in the Development and Evaluation of US Dialysis Care. <i>American Journal of Kidney Diseases</i> , 2018, 72, 560-568.	2.1	6
161	Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2018, 94, 231-234.	2.6	26
162	Predicting mortality over different time horizons: which data elements are needed?. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 176-181.	2.2	25

#	ARTICLE	IF	CITATIONS
163	Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid. <i>Arthritis Care and Research</i> , 2017, 69, 1620-1626.	1.5	34
164	Nephrologists'™ Perspectives on Defining and Applying Patient-Centered Outcomes in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 454-466.	2.2	40
165	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2017, 70, 464-475.	2.1	218
166	Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 191-198.	2.1	50
167	Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. <i>Heart</i> , 2017, 103, 818-826.	1.2	78
168	Worldwide Preparedness for Kidney Health Care. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1838.	3.8	6
169	A comparison of risk prediction methods using repeated observations: an application to electronic health records for hemodialysis. <i>Statistics in Medicine</i> , 2017, 36, 2750-2763.	0.8	41
170	Kidney Transplantation Rates Across Glomerulonephritis Subtypes in the United States. <i>Transplantation</i> , 2017, 101, 2636-2647.	0.5	7
171	Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study. <i>BMC Nephrology</i> , 2017, 18, 196.	0.8	7
172	Associations of Glycemic Control With Cardiovascular Outcomes Among US Hemodialysis Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	14
173	Drug-Eluting Stents Versus Bare Metal Stents for Percutaneous Coronary Intervention in Kidney Transplant Recipients. <i>Transplantation</i> , 2017, 101, 851-857.	0.5	3
174	Hemodialysis Hospitalizations and Readmissions: The Effects of Payment Reform. <i>American Journal of Kidney Diseases</i> , 2017, 69, 237-246.	2.1	22
175	Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex. <i>American Journal of Kidney Diseases</i> , 2017, 69, 771-779.	2.1	9
176	Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. <i>American Journal of Kidney Diseases</i> , 2017, 69, 734-743.	2.1	38
177	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2017, 92, 796-808.	2.6	40
178	Treating Depression in Patients With Advanced CKD. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1873.	3.8	8
179	A Case for More Frequent, Not Just Earlier, Nephrology Care of Patients Approaching ESRD?. <i>American Journal of Kidney Diseases</i> , 2017, 70, 155-157.	2.1	0
180	Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease. <i>Kidney International</i> , 2017, 92, 1272-1281.	2.6	31

#	ARTICLE	IF	CITATIONS
181	Patterns of NSAIDs Use and Their Association with Other Analgesic Use in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1778-1786.	2.2	28
182	Hospitalizations and Nursing Facility Stays During the Transition from CKD to ESRD on Dialysis: An Observational Study. <i>Journal of General Internal Medicine</i> , 2017, 32, 1220-1227.	1.3	11
183	Statin use and hip fractures in U.S. kidney transplant recipients. <i>BMC Nephrology</i> , 2017, 18, 145.	0.8	3
184	Consolidation in the Dialysis Industry, Patient Choice, and Local Market Competition. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 536-545.	2.2	20
185	Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2017, 69, 595-601.	2.1	21
186	Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis. <i>Journal of Nephrology</i> , 2017, 30, 281-288.	0.9	7
187	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrologyâ€™Hemodialysis (SONG-HD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2017, 69, 97-107.	2.1	148
188	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. <i>Arthritis and Rheumatology</i> , 2017, 69, 387-397.	2.9	65
189	Kidney Transplantation Outcomes across GN Subtypes in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 632-644.	3.0	63
190	Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2017, 69, 266-277.	2.1	123
191	Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 39-48.	0.8	24
192	Composing a new song for trials: the Standardized Outcomes in Nephrology (SONG) initiative. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1963-1966.	0.4	50
193	Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv386.	0.4	7
194	Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. <i>Transplantation Direct</i> , 2016, 2, e79.	0.8	30
195	Early to Dialyze. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2171.	3.8	12
196	Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data. <i>BMC Nephrology</i> , 2016, 17, 16.	0.8	26
197	Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw053.	0.4	12
198	Prevalence and determinants of unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs in Austria: a nationwide cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 90-99.	0.9	10

#	ARTICLE	IF	CITATIONS
199	Phosphate Binders: The Evidence Gap Persists. <i>American Journal of Kidney Diseases</i> , 2016, 68, 667-670.	2.1	3
200	Standardised Outcomes in Nephrologyâ€”Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. <i>Trials</i> , 2016, 17, 401.	0.7	41
201	Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. <i>Kidney International</i> , 2016, 90, 411-421.	2.6	38
202	Obstructive and Restrictive Lung Function Measures and CKD: National Health and Nutrition Examination Survey (NHANES) 2007-2012. <i>American Journal of Kidney Diseases</i> , 2016, 68, 414-421.	2.1	44
203	Federal Funding for Kidney Disease Research: A Missed Opportunity. <i>American Journal of Public Health</i> , 2016, 106, 406-407.	1.5	9
204	Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1401-1412.	2.2	24
205	Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. <i>American Journal of Transplantation</i> , 2016, 16, 1492-1502.	2.6	47
206	Differences in Initial Hemodialysis Vascular Access Use Among Glomerulonephritis Subtypes in the United States. <i>American Journal of Kidney Diseases</i> , 2016, 67, 638-647.	2.1	3
207	Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2016, 67, 271-282.	2.1	16
208	Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1459-1469.	1.2	29
209	A Cost Analysis of Tolerance Induction for Twoâ€”Haplotype Match Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2016, 16, 371-373.	2.6	3
210	Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3129-3138.	3.0	50
211	Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 444-454.	2.1	232
212	Coffee and caffeine consumption and the risk of hypertension in postmenopausal women. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 210-217.	2.2	48
213	The Dawning of a New Day in CKD Anemia Care?. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 968-970.	3.0	13
214	Kidney Function and Cardiovascular Events in Postmenopausal Women: The Impact of Race and Ethnicity in the Womenâ€™s Health Initiative. <i>American Journal of Kidney Diseases</i> , 2016, 67, 198-208.	2.1	10
215	Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2016, 67, 119-127.	2.1	18
216	The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients. <i>Clinical Laboratory</i> , 2016, 62, 1965-1972.	0.2	3

#	ARTICLE	IF	CITATIONS
217	Effects of physician payment reform on provision of home dialysis. <i>American Journal of Managed Care</i> , 2016, 22, e215-23.	0.8	17
218	Correlates of poor glycemic control among patients with diabetes initiating hemodialysis for end-stage renal disease. <i>BMC Nephrology</i> , 2015, 16, 204.	0.8	14
219	Detecting Clinically Meaningful Biomarkers with Repeated Measurements: An Illustration with Electronic Health Records. <i>Biometrics</i> , 2015, 71, 478-486.	0.8	12
220	Standardised outcomes in nephrology “ Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. <i>Trials</i> , 2015, 16, 364.	0.7	67
221	Perspectives on pregnancy in women with chronic kidney disease: systematic review of qualitative studies. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 652-661.	0.4	74
222	Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 106-113.	2.1	19
223	Research Priority Setting in Kidney Disease: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2015, 65, 674-683.	2.1	90
224	Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis. <i>Arthritis Care and Research</i> , 2015, 67, 1453-1462.	1.5	45
225	Mortality Risk of Darbepoetin Alfa Versus Epoetin Alfa in Patients With CKD: Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2015, 66, 69-74.	2.1	39
226	Adiposity Patterns and the Risk for ESRD in Postmenopausal Women. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 241-250.	2.2	24
227	Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 321-329.	0.4	17
228	The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. <i>BMJ, The</i> , 2015, 350, h246-h246.	3.0	125
229	Provider Visits and Early Vascular Access Placement in Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1990-1997.	3.0	17
230	Patient Characteristics and Outcomes by GN Subtype in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1170-1178.	2.2	47
231	Treatment of Hyperkalemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 129.	3.8	6
232	Comparison of Longer-Term Outcomes After Kidney Transplantation Between Hispanic and Non-Hispanic Whites in the United States. <i>American Journal of Transplantation</i> , 2015, 15, 499-507.	2.6	14
233	Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1577-1585.	2.9	177
234	Provider Visit Frequency and Vascular Access Interventions in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 269-277.	2.2	12

#	ARTICLE	IF	CITATIONS
235	Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. <i>American Journal of Kidney Diseases</i> , 2015, 66, 677-688.	2.1	119
236	Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 2068-2075.	0.4	12
237	Perspectives on Pregnancy in Women With CKD: A Semistructured Interview Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 951-961.	2.1	74
238	Comparative health services research across populations: the unused opportunities in big data. <i>Kidney International</i> , 2015, 87, 1094-1096.	2.6	4
239	Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1734-1740.	0.4	51
240	Treated and Untreated Kidney Failure: Quantifying an Outcome. <i>American Journal of Kidney Diseases</i> , 2015, 66, 187-189.	2.1	0
241	Timing of Dialysis Initiation—Do Health Care Setting or Provider Incentives Matter?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1321-1323.	2.2	1
242	Classifying individuals based on a densely captured sequence of vital signs: An example using repeated blood pressure measurements during hemodialysis treatment. <i>Journal of Biomedical Informatics</i> , 2015, 57, 219-224.	2.5	10
243	Use of novel oral anticoagulants in patients with end-stage renal disease. <i>Hemodialysis International</i> , 2015, 19, 150-153.	0.4	6
244	Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 193-205.	1.0	13
245	Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0135674.	1.1	3
246	Coronary artery bypass graft type and outcomes in maintenance dialysis. <i>Journal of Cardiovascular Surgery</i> , 2015, 56, 463-71.	0.3	5
247	Physician Visits and 30-Day Hospital Readmissions in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2079-2087.	3.0	82
248	Prognostic Stratification in Older Adults Commencing Dialysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 1033-1039.	1.7	20
249	Still unresolved: warfarin in ESRD with atrial fibrillation. <i>Nature Reviews Nephrology</i> , 2014, 10, 244-245.	4.1	5
250	Addressing Missing Data in Clinical Studies of Kidney Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1328-1335.	2.2	59
251	Comparison of Medicare Claims Versus Physician Adjudication for Identifying Stroke Outcomes in the Women's Health Initiative. <i>Stroke</i> , 2014, 45, 815-821.	1.0	43
252	Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 515-525.	0.9	8

#	ARTICLE	IF	CITATIONS
253	Patients' Perspectives on Hemodialysis Vascular Access: A Systematic Review of Qualitative Studies. American Journal of Kidney Diseases, 2014, 64, 937-953.	2.1	105
254	DIALYSIS VASCULAR ACCESS. Nephrology Dialysis Transplantation, 2014, 29, iii246-iii262.	0.4	2
255	Prevention of Acute Kidney Injury Using Vasoactive or Antiplatelet Treatment. JAMA - Journal of the American Medical Association, 2014, 312, 2221.	3.8	12
256	Medicare Reimbursement Reform for Provider Visits and Health Outcomes in Patients on Hemodialysis. Forum for Health Economics and Policy, 2014, 17, 53-77.	0.2	12
257	State Medicaid Coverage, ESRD Incidence, and Access to Care. Journal of the American Society of Nephrology: JASN, 2014, 25, 1321-1329.	3.0	40
258	Thienopyridine Use After Coronary Stenting in Low Income Patients Enrolled in Medicare Part D Receiving Maintenance Dialysis. Journal of the American Heart Association, 2014, 3, e001356.	1.6	10
259	Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States (1995-2010). JAMA Internal Medicine, 2014, 174, 699.	2.6	17
260	Near-Term Prediction of Sudden Cardiac Death in Older Hemodialysis Patients Using Electronic Health Records. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 82-91.	2.2	24
261	Use of Medicare Data to Identify Coronary Heart Disease Outcomes in the Women's Health Initiative. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 157-162.	0.9	76
262	Thematic Synthesis of Qualitative Studies on Patient and Caregiver Perspectives on End-of-Life Care in CKD. American Journal of Kidney Diseases, 2014, 63, 913-927.	2.1	80
263	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder Among US Hemodialysis Patients": The Calm Before the 2016 Storm?. American Journal of Kidney Diseases, 2014, 63, 854-858.	2.1	1
264	Qualitative Research in CKD: An Overview of Methods and Applications. American Journal of Kidney Diseases, 2014, 64, 338-346.	2.1	57
265	Warfarin Treatment in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. JAMA - Journal of the American Medical Association, 2014, 311, 913.	3.8	17
266	Heparin Use in Hemodialysis Patients following Gastrointestinal Bleeding. American Journal of Nephrology, 2014, 40, 300-307.	1.4	5
267	Temporal Trends in the Incidence, Treatment and Outcomes of Hip Fracture After First Kidney Transplantation in the United States. American Journal of Transplantation, 2014, 14, 943-951.	2.6	70
268	Increased Mortality Associated With Digoxin in Contemporary Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 64, 660-668.	1.2	189
269	Earlier- Versus Later-Start Peritoneal Dialysis: Not a Moment Too Soon?. American Journal of Kidney Diseases, 2014, 63, 741-744.	2.1	1
270	Epidemiologic and Statistical Methods for Comparative Effectiveness Research. Heart Failure Clinics, 2013, 9, 29-36.	1.0	9



#	ARTICLE	IF	CITATIONS
271	Trends in Acute Kidney Injury, Associated Use of Dialysis, and Mortality After Cardiac Surgery, 1999 to 2008. <i>Annals of Thoracic Surgery</i> , 2013, 95, 20-28.	0.7	82
272	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Trends Through December 2011": Results From Year One. <i>American Journal of Kidney Diseases</i> , 2013, 61, 346-348.	2.1	1
273	Trends in Relative Mortality Between Hispanic and Non-Hispanic Whites Initiating Dialysis: A Retrospective Study of the US Renal Data System. <i>American Journal of Kidney Diseases</i> , 2013, 62, 312-321.	2.1	32
274	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle": Iron(y) Abounds 2 Years Later. <i>American Journal of Kidney Diseases</i> , 2013, 62, 1217-1220.	2.1	7
275	More Evidence on an Abominable Pairing. <i>Circulation</i> , 2013, 127, 560-562.	1.6	7
276	Determinants of Peritoneal Dialysis Technique Failure in Incident us Patients. <i>Peritoneal Dialysis International</i> , 2013, 33, 155-166.	1.1	76
277	Strategies for Postmarketing Surveillance of Drugs and Devices in Patients with ESRD Undergoing Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2213-2220.	2.2	1
278	Temporal Trends in the Incidence, Treatment, and Outcomes of Hip Fracture in Older Patients Initiating Dialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1336-1342.	2.2	67
279	Fostering Innovation, Advancing Patient Safety: The Kidney Health Initiative. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1609-1617.	2.2	47
280	Variation in Nephrologist Visits to Patients on Hemodialysis across Dialysis Facilities and Geographic Locations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 987-994.	2.2	33
281	Kidney Disease and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 697.	3.8	0
282	Use and safety of heparin-free maintenance hemodialysis in the USA. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1589-1602.	0.4	26
283	Predicting the Outcomes of Rhabdomyolysis. <i>JAMA Internal Medicine</i> , 2013, 173, 1828.	2.6	1
284	Outcomes After Kidney Transplantation of Patients Previously Diagnosed With Atrial Fibrillation. <i>American Journal of Transplantation</i> , 2013, 13, 1566-1575.	2.6	41
285	Multivessel coronary revascularization and outcomes in kidney transplant recipients. <i>Transplant International</i> , 2013, 26, 1080-1087.	0.8	8
286	Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. <i>Arthritis and Rheumatism</i> , 2013, 65, 753-763.	6.7	357
287	Assessments of Causal Effects "Theoretically Sound, Practically Unattainable, and Clinically Not So Relevant. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 520-522.	2.2	2
288	Differences in Access to Kidney Transplantation between Hispanic and Non-Hispanic Whites by Geographic Location in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2149-2157.	2.2	50

#	ARTICLE	IF	CITATIONS
289	Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2013, 24, 1151-1158.	3.0	145
290	Effect of Conversion From Ciclosporin to Tacrolimus on Endothelial Progenitor Cells in Stable Long-Term Kidney Transplant Recipients. Transplantation, 2013, 95, 1338-1345.	0.5	6
291	Intravenous Iron Supplementation Practices and Short-Term Risk of Cardiovascular Events in Hemodialysis Patients. PLoS ONE, 2013, 8, e78930.	1.1	54
292	Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. Journal of Clinical & Cellular Immunology, 2013, 04, 179.	1.5	5
293	Trends in the incidence of intestinal perforation in US dialysis patients (1992-2005). Journal of Nephrology, 2013, 26, 281-288.	0.9	4
294	Hispanic Ethnicity and Vascular Access Use in Patients Initiating Hemodialysis in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 289-296.	2.2	32
295	Use of Secondary Prevention Medications among Adults with Reduced Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 604-611.	2.2	3
296	Trends in Acute Nonvariceal Upper Gastrointestinal Bleeding in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2012, 23, 495-506.	3.0	92
297	Anticoagulation for atrial fibrillation in patients on dialysis. Current Opinion in Nephrology and Hypertension, 2012, 21, 600-606.	1.0	30
298	Multivessel Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in ESRD. Journal of the American Society of Nephrology: JASN, 2012, 23, 2042-2049.	3.0	128
299	Trends in the Incidence of Atrial Fibrillation in Older Patients Initiating Dialysis in the United States. Circulation, 2012, 126, 2293-2301.	1.6	88
300	Validation of Reported Predialysis Nephrology Care of Older Patients Initiating Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1078-1085.	3.0	39
301	Treated and Untreated Kidney Failure in Older Adults. JAMA - Journal of the American Medical Association, 2012, 307, 2545-6.	3.8	8
302	Quantifying the benefit of early living-donor renal transplantation with a simulation model of the Dutch renal replacement therapy population. Nephrology Dialysis Transplantation, 2012, 27, 429-434.	0.4	9
303	Comparative effectiveness research: what is it and why do we need it in nephrology?. Nephrology Dialysis Transplantation, 2012, 27, 2156-2161.	0.4	19
304	Altitude and the risk of cardiovascular events in incident US dialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 2411-2417.	0.4	21
305	Saving the Kidneys by Sparing Intravenous Chloride?. JAMA - Journal of the American Medical Association, 2012, 308, 1583.	3.8	14
306	Predialysis Nephrology Care of Older Individuals Approaching End-Stage Renal Disease. Seminars in Dialysis, 2012, 25, 628-632.	0.7	6

#	ARTICLE	IF	CITATIONS
307	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Trends Through August 2011": An ESA Confluence. <i>American Journal of Kidney Diseases</i> , 2012, 60, 165-167.	2.1	6
308	Causal or Casual?"The Association Between Consumption of Artificially Sweetened Carbonated Beverages and Vascular Disease. <i>Journal of General Internal Medicine</i> , 2012, 27, 1100-1101.	1.3	1
309	Use and Safety of Unfractionated Heparin for Anticoagulation During Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2012, 60, 473-486.	2.1	70
310	The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs. <i>PLoS ONE</i> , 2012, 7, e31894.	1.1	45
311	Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. <i>Arthritis and Rheumatism</i> , 2012, 64, 2669-2676.	6.7	163
312	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Trends Through April 2011": No Surprises Yet. <i>American Journal of Kidney Diseases</i> , 2012, 59, 312-314.	2.1	1
313	Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. <i>Journal of Nephrology</i> , 2012, 25, 341-353.	0.9	21
314	Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. <i>Clinical Nephrology</i> , 2012, 78, 181-188.	0.4	12
315	Tackling the Achilles' Heel of Hemodialysis. <i>New England Journal of Medicine</i> , 2011, 364, 372-374.	13.9	10
316	Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. <i>American Heart Journal</i> , 2011, 162, 324-330.	1.2	31
317	Incidence, Correlates, and Consequences of Acute Kidney Injury in Patients With Pulmonary Arterial Hypertension Hospitalized With Acute Right-Side Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 533-539.	0.7	44
318	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: Challenges in Comparative Effectiveness Using Medicare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 674-682.	2.3	7
319	The 2011 ESRD Prospective Payment System: An Uncontrolled Experiment. <i>American Journal of Kidney Diseases</i> , 2011, 57, 542-546.	2.1	15
320	Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States. <i>American Journal of Kidney Diseases</i> , 2011, 58, 409-417.	2.1	110
321	Air Pollution and Coronary Risk in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2011, 58, 506-507.	2.1	4
322	Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 57-65.	0.9	8
323	Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. <i>Arthritis Care and Research</i> , 2011, 63, 1642-1653.	1.5	26
324	Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. <i>Arthritis and Rheumatism</i> , 2011, 63, 1681-1688.	6.7	197

#	ARTICLE	IF	CITATIONS
325	End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. <i>Arthritis and Rheumatism</i> , 2011, 63, 1988-1997.	6.7	93
326	Posttransplantation Anemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1794-1801.	2.2	57
327	Against TREATing All Patients Alike. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1-2.	3.0	19
328	Kidney Function and Long-Term Medication Adherence after Myocardial Infarction in the Elderly. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 864-869.	2.2	24
329	Predialysis Nephrology Care of Older Patients Approaching End-stage Renal Disease. <i>Archives of Internal Medicine</i> , 2011, 171, 1371.	4.3	62
330	Comparative Effectiveness of Calcium-Containing Phosphate Binders in Incident U.S. Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 175-183.	2.2	38
331	Potential Effects of the New Medicare Prospective Payment System on Drug Prescription in End-Stage Renal Disease Care. <i>Blood Purification</i> , 2011, 31, 66-69.	0.9	8
332	World Kidney Day 2011. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 397-398.	3.0	5
333	The Effect of Altitude Change on Anemia Treatment Response in Hemodialysis Patients. <i>American Journal of Epidemiology</i> , 2011, 173, 768-777.	1.6	13
334	What Caused Excess Strokes in Patients Randomized to Darbepoetin in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)? <i>Circulation</i> , 2011, 124, 2805-2808.	1.6	5
335	The Increasing Prevalence of Atrial Fibrillation among Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 349-357.	3.0	234
336	Effectiveness and Safety of Warfarin Initiation in Older Hemodialysis Patients with Incident Atrial Fibrillation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2662-2668.	2.2	250
337	Impact of reimbursement changes on statin use among patients with diabetes in Austria. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 89-94.	1.0	10
338	Kidney Disease and Antihypertensive Medication Adherence: The Need for Improved Measurement Tools. <i>American Journal of Kidney Diseases</i> , 2010, 56, 423-426.	2.1	5
339	Off-Label Use of Phosphate Binders in Non-Dialysis-Dependent CKD. <i>American Journal of Kidney Diseases</i> , 2010, 56, 813-816.	2.1	1
340	The Challenges of Cost-Effectiveness Analyses for the Clinician. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1023-1025.	2.1	2
341	On the relative safety of intravenous iron formulations: New answers, new questions. <i>American Journal of Hematology</i> , 2010, 85, 643-644.	2.0	14
342	Propensity scores in the presence of effect modification: A case study using the comparison of mortality on hemodialysis versus peritoneal dialysis. <i>Emerging Themes in Epidemiology</i> , 2010, 7, 1.	1.2	27

#	ARTICLE	IF	CITATIONS
343	Confusion about the Appropriate Use of Erythropoiesis-Stimulating Agents in Patients Undergoing Maintenance Dialysis. <i>Seminars in Dialysis</i> , 2010, 23, 486-491.	0.7	4
344	Temporal Trends in Adherence to Cardiovascular Medications in Elderly Patients After Hospitalization for Heart Failure. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 548-554.	2.3	39
345	Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 857.	3.8	99
346	ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus. <i>Drugs and Aging</i> , 2010, 27, 87-94.	1.3	18
347	Late referral to paediatric renal failure service impairs access to pre-emptive kidney transplantation in children. <i>Archives of Disease in Childhood</i> , 2010, 95, 634-638.	1.0	27
348	Chronic on Acute Renal Failure. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1227.	3.8	51
349	Lessons from Geographic Variations in Predialysis Nephrology Care. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 930-932.	3.0	2
350	Association Between Altitude and Mortality in Incident Dialysis Patientsâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2442.	3.8	1
351	Evolving Statistical Methods to Facilitate Evaluation of the Causal Association Between Erythropoiesis-Stimulating Agent Dose and Mortality in Nonexperimental Research: Strengths and Limitations. <i>American Journal of Kidney Diseases</i> , 2009, 54, 554-560.	2.1	27
352	Greater Epoetin alfa (EPO) doses and shortâ€”term mortality risk among hemodialysis patients with hemoglobin levels less than 11â€”g/dL. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 932-940.	0.9	25
353	Altitude and All-Cause Mortality in Incident Dialysis Patients. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 508.	3.8	49
354	Effect of Hemodialysis Before Transplant Surgery on Renal Allograft Functionâ€”A Pair of Randomized Controlled Trials. <i>Transplantation</i> , 2009, 88, 1377-1385.	0.5	21
355	Use of recommended medications after myocardial infarction in Austria. <i>European Journal of Epidemiology</i> , 2008, 23, 153-162.	2.5	15
356	Medication Adherence After Myocardial Infarction: A Long Way Left To Go. <i>Journal of General Internal Medicine</i> , 2008, 23, 216-218.	1.3	28
357	Trends in adherence to secondary prevention medications in elderly postâ€”myocardial infarction patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 1189-1196.	0.9	121
358	Gender Differences in the Management and Prognosis of Myocardial Infarction Among Patients â‰¥ 65 Years of Age. <i>American Journal of Cardiology</i> , 2008, 101, 1531-1536.	0.7	24
359	Phosphate Binder Choice in Dialysis Patients: A Call for Evidence-Based Rather Than Marketing-Based Clinical Practice. <i>American Journal of Kidney Diseases</i> , 2008, 51, 362-365.	2.1	22
360	Approaching the End of the Homocysteine Hype?. <i>American Journal of Kidney Diseases</i> , 2008, 51, 549-553.	2.1	3

#	ARTICLE	IF	CITATIONS
361	Educational Level as a Determinant of Access to and Outcomes After Kidney Transplantation in the United States. <i>American Journal of Kidney Diseases</i> , 2008, 51, 811-818.	2.1	60
362	Improvements in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular Drugs After Discharge. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1247-1254.	1.2	164
363	Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. <i>International Journal of Cardiology</i> , 2008, 125, 172-177.	0.8	10
364	Nonselective and Cyclooxygenase-2-Selective NSAIDs and Acute Kidney Injury. <i>American Journal of Medicine</i> , 2008, 121, 1092-1098.	0.6	80
365	Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy. <i>Archives of Internal Medicine</i> , 2008, 168, 2368.	4.3	103
366	Pottransplantation Anemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S49-S55.	2.2	68
367	The Effect of Altitude on Dosing and Response to Erythropoietin in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1389-1395.	3.0	62
368	Associations of Kidney Function with Cardiovascular Medication Use after Myocardial Infarction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1415-1422.	2.2	38
369	No Associations between Prolactin Concentrations and Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2007, 27, 390-396.	1.4	1
370	Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease. <i>Kidney International</i> , 2007, 71, 938-945.	2.6	35
371	Benzodiazepine use and mortality of incident dialysis patients in the United States. <i>Kidney International</i> , 2007, 72, 1388-1393.	2.6	64
372	Cardiovascular Risk and the Thiazolidinediones. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1216.	3.8	30
373	Renal dysfunction increases the risk of saphenous vein graft occlusion: Results from the Post-CABG trial. <i>Atherosclerosis</i> , 2007, 193, 414-420.	0.4	14
374	Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. <i>Kidney International</i> , 2007, 71, 153-158.	2.6	172
375	Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. <i>Transplant International</i> , 2007, 20, 247-255.	0.8	35
376	A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. <i>Transplant International</i> , 2007, 20, 505-511.	0.8	16
377	Ten-Year Trends of Cardiovascular Drug Use After Myocardial Infarction Among Community-Dwelling Persons $\geq 65$ Years of Age. <i>American Journal of Cardiology</i> , 2007, 100, 1061-1067.	0.7	45
378	Predialysis Nephrologist Care and Access to Kidney Transplantation in the United States. <i>American Journal of Transplantation</i> , 2007, 7, 872-879.	2.6	50

#	ARTICLE	IF	CITATIONS
379	Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. <i>Pediatric Nephrology</i> , 2007, 22, 1189-1193.	0.9	47
380	Genetic Aspects of Hyperhomocysteinemia in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2006, 26, 8-13.	0.6	7
381	The Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use During Postischemic Acute Transplant Failure and Renal Allograft Survival. <i>Transplantation</i> , 2006, 82, 1441-1448.	0.5	23
382	Endothelial Progenitor Cells in Kidney Transplant Recipients. <i>Transplantation</i> , 2006, 81, 599-606.	0.5	27
383	Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. <i>Transplant International</i> , 2006, 19, 629-635.	0.8	69
384	Angiotensin inhibition after myocardial infarction: Does drug class matter?. <i>Journal of General Internal Medicine</i> , 2006, 21, 1242-1247.	1.3	9
385	Poor Short-Term Survival and Low Use of Cardiovascular Medications in Elderly Dialysis Patients After Acute Myocardial Infarction. <i>American Journal of Kidney Diseases</i> , 2006, 47, 301-308.	2.1	59
386	Prognostic Associations Between Lipid Markers and Outcomes in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2006, 47, 509-517.	2.1	11
387	Surrogate Markers in Clinical Studies: Problems Solved or Created?. <i>American Journal of Kidney Diseases</i> , 2006, 48, 159-166.	2.1	43
388	A prospective study of anaemia and long-term outcomes in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3559-3566.	0.4	64
389	Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Type 1 Receptor Antagonist Therapy Is Associated with Prolonged Patient and Graft Survival after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 889-899.	3.0	246
390	Associations between Demographic Factors and Provider Structures on Cost and Length of Stay for Hemodialysis Patients with Vascular Access Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 455-461.	2.2	9
391	Efficacy and Safety of Angiotensin II Receptor Blockade in Elderly Patients With Diabetes. <i>Diabetes Care</i> , 2006, 29, 2210-2217.	4.3	55
392	Kidney Function and Use of Recommended Medications after Myocardial Infarction in Elderly Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 796-801.	2.2	32
393	Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1688-1694.	3.0	415
394	Assessing Health State Utilities in Elderly Patients at Cardiovascular Risk. <i>Medical Decision Making</i> , 2006, 26, 247-254.	1.2	13
395	Incidence of end-stage renal disease in patients with type 1 diabetes was 7.8% at 30 years after diagnosis. <i>ACP Journal Club</i> , 2006, 144, 51.	0.1	0
396	Incidence of end-stage renal disease in patients with type 1 diabetes was 7.8% at 30 years after diagnosis. <i>ACP Journal Club</i> , 2006, 144, 51.	0.1	0

#	ARTICLE	IF	CITATIONS
397	Long-Term Patient and Graft Survival in the Eurotransplant Senior Program: A Single-Center Experience. <i>Transplantation</i> , 2005, 80, 582-589.	0.5	42
398	Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B12 in kidney transplant recipients. <i>Kidney International</i> , 2005, 67, 1980-1985.	2.6	20
399	Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. <i>Kidney International</i> , 2005, 68, 2857-2862.	2.6	11
400	A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. <i>Haemophilia</i> , 2005, 11, 261-269.	1.0	26
401	Identification of Individuals With CKD From Medicare Claims Data: A Validation Study. <i>American Journal of Kidney Diseases</i> , 2005, 46, 225-232.	2.1	198
402	Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With Diabetes. <i>American Journal of Kidney Diseases</i> , 2005, 46, 1080-1087.	2.1	72
403	The Hepatotoxicity of Antifungal Medications in Bone Marrow Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2005, 41, 301-307.	2.9	59
404	Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients: A Prospective Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 255-260.	3.0	51
405	Habitual Caffeine Intake and the Risk of Hypertension in Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2330.	3.8	231
406	Propensity scores: help or hype?. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1671-1673.	0.4	107
407	Patient and Graft Survival in Older Kidney Transplant Recipients: Does Age Matter?. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1052-1060.	3.0	96
408	Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction*. <i>Clinical Transplantation</i> , 2004, 18, 341-348.	0.8	23
409	Patterns of co-occurrence of three single nucleotide polymorphisms of the 5,10-methylenetetrahydrofolate reductase gene in kidney transplant recipients. <i>European Journal of Clinical Investigation</i> , 2004, 34, 613-618.	1.7	11
410	Effects of TCN2 776C>G on vitamin B12, folate, and total homocysteine levels in kidney transplant patients. <i>Kidney International</i> , 2004, 65, 1877-1881.	2.6	12
411	A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. <i>Kidney International</i> , 2004, 66, 1239-1247.	2.6	72
412	C-Reactive Protein and Body Mass Index Independently Predict Mortality in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 1148-1154.	2.6	59
413	Percentage of Hypochromic Red Blood Cells is an Independent Risk Factor for Mortality in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 2075-2081.	2.6	43
414	How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 11-19.	0.9	86



#	ARTICLE	IF	CITATIONS
415	Pharmacoevidence of Anemia in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2004, 15, 1347-1352.	3.0	123
416	Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients. Atherosclerosis, 2004, 174, 43-48.	0.4	34
417	KNOWLEDGE AND ATTITUDE REGARDING ORGAN DONATION AMONG MEDICAL STUDENTS AND PHYSICIANS. Transplantation, 2004, 77, 1714-1718.	0.5	113
418	Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgery. American Journal of Kidney Diseases, 2003, 41, 84-89.	2.1	63
419	Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients. Kidney International, 2003, 63, 2280-2285.	2.6	46
420	The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney International, 2003, 64, 295-304.	2.6	66
421	Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney International, 2003, 64, 1046-1049.	2.6	82
422	The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. Kidney International, 2003, 63, 1836-1842.	2.6	29
423	A Propensity Analysis of Late Versus Early Nephrologist Referral and Mortality on Dialysis. Journal of the American Society of Nephrology: JASN, 2003, 14, 486-492.	3.0	200
424	Hetastarch and Bleeding Complications After Coronary Artery Surgery. Chest, 2003, 124, 1437-1442.	0.4	64
425	Comparing Mortality of Elderly Patients on Hemodialysis versus Peritoneal Dialysis: A Propensity Score Approach. Journal of the American Society of Nephrology: JASN, 2002, 13, 2353-2362.	3.0	145
426	Late nephrologist referral and access to renal transplantation <sup>1</sup> . Transplantation, 2002, 73, 1918-1923.	0.5	59
427	Nephrologist Care and Mortality in Patients With Chronic Renal Insufficiency. Archives of Internal Medicine, 2002, 162, 2002.	4.3	126
428	Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. Journal of Clinical Epidemiology, 2002, 55, 711-716.	2.4	127
429	Preventive health care measures before and after start of renal replacement therapy. Journal of General Internal Medicine, 2002, 17, 588-595.	1.3	18
430	Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment. Medical Decision Making, 2002, 22, 417-430.	1.2	139
431	Determinants of delayed nephrologist referral in patients with chronic kidney disease. American Journal of Kidney Diseases, 2001, 38, 1178-1184.	2.1	98
432	Late referral and modality choice in end-stage renal disease. Kidney International, 2001, 60, 1547-1554.	2.6	77

#	ARTICLE	IF	CITATIONS
433	Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease. Expert Opinion on Investigational Drugs, 2000, 9, 2637-2652.	1.9	6
434	Effect of High Dose Folic Acid Therapy on Hyperhomocysteinemia in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2000, 11, 1106-1116.	3.0	111